A Patients' Perspective Towards the Injection Devices for Humira® and Imraldi® in a Nationwide Switching Program.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Gunnarsdottir, Anna I
Love, Thorvardur J
Davidsdottir, Loa G
Thorleifsdottir, Ragna H
MetadataShow full item record
CitationKarlsdottir K, Gunnarsdottir AI, Grondal G, et al. A Patients' Perspective Towards the Injection Devices for Humira® and Imraldi® in a Nationwide Switching Program. Front Med (Lausanne). 2022;9:799494. Published 2022 Jan 27. doi:10.3389/fmed.2022.799494
AbstractObjective: Due to a tender process in Iceland, all patients on Humira® were switched nationwide to its biosimilar Imraldi® in March 2019. The study aimed to explore the patient's perspective of the Humira® and Imraldi® injection devices. Methods: A standard telephone interview was carried out among patients with inflammatory arthritis, inflammatory bowel disease and psoriasis, who underwent this nationwide switching program a few months earlier. Results: The response rate was 84.5% (n = 198). The average age was 50.8 years, and 53.5% were female. The patients self-administered the drugs in 96% of the cases. The majority (90.5%) stated that they received individualized instruction on using the Humira® pen, compared to 18.2% who accepted instruction in the case of the Imraldi® pen. Almost half (46.6%) of the patients found it more difficult to use the Imraldi® pen than the Humira® pen, while only 12.5% found the Imraldi® pen easier to use. Firstly, these differences were due to more painful insertion of the needle (62.2%) and secondly, due to the experience, the injection process was different (63.0%). Conclusion: Patients with inflammatory disorders who have been treated regularly with adalimumab preferred the Humira® injection device over the Imraldi® device, according to our results. After all, these injection devices' structure and content are not the same, although both contain the same active ingredient, i.e. adalimumab. Our results highlight the importance of thorough information, not only with an information letter but also with the possibilities for individualized introduction in planning switching to biosimilars. Keywords: Humira; Imraldi; adalimumab; injection devices; medicine administration at home.
DescriptionTo access publisher's full text version of this article, please click on the hyperlink in Additional Links field or click on the hyperlink at the top of the page marked Download
RightsCopyright © 2022 Karlsdottir, Gunnarsdottir, Grondal, Love, Stefansdottir, Davidsdottir, Thorleifsdottir and Gudbjornsson.
- Nurse and Patient Perceptions and Preferences for Subcutaneous Autoinjectors for Inflammatory Joint or Bowel Disease: Findings from a European Survey.
- Authors: Fenwick S, Thakur K, Munro D
- Issue date: 2019 Jun
- Demonstration of functional similarity of a biosimilar adalimumab SB5 to Humira<sup>®</sup>.
- Authors: Lee JJ, Yang J, Lee C, Moon Y, Ahn S, Yang J
- Issue date: 2019 Mar
- Overview of Humira® Biosimilars: Current European Landscape and Future Implications.
- Authors: Coghlan J, He H, Schwendeman AS
- Issue date: 2021 Apr
- Patients' and nurses' preferences for autoinjectors for rheumatoid arthritis: results of a European survey.
- Authors: Tischer B, Mehl A
- Issue date: 2018
- Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn's Disease: A Prospective Study.
- Authors: Ribaldone DG, Tribocco E, Rosso C, Armandi A, Vernero M, Bugianesi E, Astegiano M, Saracco GM, Caviglia GP
- Issue date: 2021 Jul 30